Patents Assigned to H. Lundbeck A/S
  • Publication number: 20170304267
    Abstract: The present invention relates to the use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in patients suffering from a CNS disease, in particular patients with Parkinson's disease, wherein balance, gait or movement is impaired.
    Type: Application
    Filed: April 25, 2017
    Publication date: October 26, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Inge E.M. de Jong, Aaron Kucinski, Martin Sarter
  • Publication number: 20170298072
    Abstract: The present invention provides triazolopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 19, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Mikkel Jessing
  • Patent number: 9789085
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: October 17, 2017
    Assignee: H. LUNDBECK A/S
    Inventors: Ellen Schmidt, Johan Areberg
  • Publication number: 20170291874
    Abstract: The present invention relates to the preparation of N-(2-(6-fluoro-1H-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine (Compound I), INN-name idalopirdine, and pharmaceutically acceptable salts thereof:
    Type: Application
    Filed: April 6, 2017
    Publication date: October 12, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Mikkel Fog Jacobsen, Florian Anton Martin Huber
  • Publication number: 20170291903
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: June 6, 2017
    Publication date: October 12, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl
  • Publication number: 20170291901
    Abstract: The present invention provides 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 12, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Karsten Juhl, Mikkel Jessing, Morten Langgård, Paulo Jorge Vieira Vital, Mauro Marigo, Jan Kehler, Lars Kyhn Rasmussen
  • Publication number: 20170275294
    Abstract: The present invention relates to new nalmefene salts which salts fall within at least one of the two following categories: non-hydrate forming salts and non-solvate forming salts. In particular, the invention relates to the hydrogen adipate salt, the hydrogen malonate salt, the lactate salt, the hydrogen fumarate salt, the hydrogen succinate salt, the benzene sulfonate salt, the hydrogen maleate salt and the salicylate salt of nalmefene. The present invention also relates to such salts for use in therapy.
    Type: Application
    Filed: June 12, 2017
    Publication date: September 28, 2017
    Applicant: H. Lundbeck A/S
    Inventor: Heidi Lopez De Diego
  • Publication number: 20170267761
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: July 12, 2016
    Publication date: September 21, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Søren Christensen, Jan Egebjerg, Jeffrey B. Stavenhagen, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • Publication number: 20170267664
    Abstract: The present invention provides Quinazolin-THF-amines as PDE I inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: June 5, 2017
    Publication date: September 21, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård
  • Patent number: 9744166
    Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: August 29, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Nicholas Moore, Marianne Dragheim
  • Publication number: 20170239226
    Abstract: The present invention is directed to N-substituted-5-substituted phthalamic acids which of formula (A). The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, motoneuron disease, peripheral neuropathies, pain, neuroinflammation or atherosclerosis such as Alzheimer's disease and Parkinson's disease.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 24, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Phillip James Maltas, Stephen Watson, Morten Langgård, Laurent David
  • Publication number: 20170240611
    Abstract: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of mental and behavioral disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 24, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Simon Glerup Pedersen, Ulrich Bolcho, Kimmo Jensen, Anders Nykjaer
  • Patent number: 9725458
    Abstract: The present invention relates to new nalmefene salts which salts fall within at least one of the two following categories: non-hydrate forming salts and non-solvate forming salts. In particular, the invention relates to the hydrogen adipate salt, the hydrogen malonate salt, the lactate salt, the hydrogen fumarate salt, the hydrogen succinate salt, the benzene sulfonate salt, the hydrogen maleate salt and the salicylate salt of nalmefene. The present invention also relates to such salts for use in therapy.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 8, 2017
    Assignee: H. Lundbeck A/S
    Inventor: Heidi Lopez De Diego
  • Publication number: 20170217950
    Abstract: The present invention provides bicyclo[3.2.1]octyl amide derivatives of formula (I): wherein L, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods using the same.
    Type: Application
    Filed: April 18, 2017
    Publication date: August 3, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Guiying Li, Hao Zhou, Jesse Weiss, Dario Doller, James Ford Burns
  • Patent number: 9718832
    Abstract: The present invention provides hexahydrofuropyrroles as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 1, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård
  • Publication number: 20170202836
    Abstract: The present invention is directed to benzamide-containing compounds of formula I or pharmaceutically acceptable salts thereof which inhibit the P2X7 receptor, and their use in the treatment of epilepsy.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 20, 2017
    Applicant: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang, Allen T. Hopper
  • Patent number: 9708280
    Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: July 18, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Thomas Ruhland, Garrick Paul Smith, Benny Bang-Andersen, Ask Puschl, Ejner Knud Moltzen, Kim Andersen
  • Patent number: 9701665
    Abstract: The present invention provides Quinazolin-THF-amines as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: July 11, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård
  • Patent number: 9687473
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 27, 2017
    Assignee: H. LUNDBECK A/S
    Inventors: Ellen Schmidt, Johan Areberg
  • Patent number: 9682967
    Abstract: The present invention is directed to N-substituted-5-substituted phthalamic acids which of formula (A). The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, motorneuron disease, peripheral neuropathies, pain, neuroinflammation or atherosclerosis such as Alzheimer's disease and Parkinson's disease.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: June 20, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Philip James Maltas, Stephen Watson, Morten Langg{hacek over (a)}rd, Laurent David